240 related articles for article (PubMed ID: 10862503)
1. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.
Taavitsainen P; Anttila M; Nyman L; Karnani H; Salonen JS; Pelkonen O
Pharmacol Toxicol; 2000 May; 86(5):215-21. PubMed ID: 10862503
[TBL] [Abstract][Full Text] [Related]
2. P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine.
Benetton SA; Fang C; Yang YO; Alok R; Year M; Lin CC; Yeh LT
Drug Metab Pharmacokinet; 2007 Apr; 22(2):78-87. PubMed ID: 17495414
[TBL] [Abstract][Full Text] [Related]
3. Diazinon is activated by CYP2C19 in human liver.
Kappers WA; Edwards RJ; Murray S; Boobis AR
Toxicol Appl Pharmacol; 2001 Nov; 177(1):68-76. PubMed ID: 11708902
[TBL] [Abstract][Full Text] [Related]
4. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
5. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
Kivistö KT; Wang JS; Backman JT; Nyman L; Taavitsainen P; Anttila M; Neuvonen PJ
Eur J Clin Pharmacol; 2001 Apr; 57(1):37-42. PubMed ID: 11372588
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline.
Laine K; Anttila M; Nyman L; Wahlberg A; Bertilsson L
Eur J Clin Pharmacol; 2001 May; 57(2):137-42. PubMed ID: 11417445
[TBL] [Abstract][Full Text] [Related]
7. Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes.
Nakajima M; Kobayashi K; Oshima K; Shimada N; Tokudome S; Chiba K; Yokoi T
Xenobiotica; 1999 Sep; 29(9):885-98. PubMed ID: 10548449
[TBL] [Abstract][Full Text] [Related]
8. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
[TBL] [Abstract][Full Text] [Related]
9. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor.
VandenBranden M; Ring BJ; Binkley SN; Wrighton SA
Pharmacogenetics; 1996 Feb; 6(1):81-91. PubMed ID: 8845864
[TBL] [Abstract][Full Text] [Related]
10. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.
Wienkers LC; Wurden CJ; Storch E; Kunze KL; Rettie AE; Trager WF
Drug Metab Dispos; 1996 May; 24(5):610-4. PubMed ID: 8723744
[TBL] [Abstract][Full Text] [Related]
11. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
Ramírez J; Innocenti F; Schuetz EG; Flockhart DA; Relling MV; Santucci R; Ratain MJ
Drug Metab Dispos; 2004 Sep; 32(9):930-6. PubMed ID: 15319333
[TBL] [Abstract][Full Text] [Related]
12. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.
Hidestrand M; Oscarson M; Salonen JS; Nyman L; Pelkonen O; Turpeinen M; Ingelman-Sundberg M
Drug Metab Dispos; 2001 Nov; 29(11):1480-4. PubMed ID: 11602525
[TBL] [Abstract][Full Text] [Related]
13. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
[TBL] [Abstract][Full Text] [Related]
14. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
Eagling VA; Tjia JF; Back DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
[TBL] [Abstract][Full Text] [Related]
15. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
16. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
17. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
Hyland R; Roe EG; Jones BC; Smith DA
Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
[TBL] [Abstract][Full Text] [Related]
18. Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.
Wang JS; Backman JT; Wen X; Taavitsainen P; Neuvonen PJ; Kivistö KT
Pharmacol Toxicol; 1999 Nov; 85(5):201-5. PubMed ID: 10608481
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4.
Feierman DE; Lasker JM
Drug Metab Dispos; 1996 Sep; 24(9):932-9. PubMed ID: 8886601
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
